EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biocomparables huérfanos en Latinoamérica: la urgencia de una regulación científica diferenciada

Eduardo Pérez-Campos, Efrén Emmanuel Jarquín González, Hector A. Cabrera-Fuentes

Latin american journal of clinical sciences and medical technology · 2025

DOI: 10.34141/ljcs1471963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, 2025. Verfasst von Eduardo Pérez-Campos und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Welcome to FDA's Center for Drug Evaluation and Research's (CDER) 14th annual report, Advancing Health Through Innovation: New Drug Therapy Approvals.The 2024 New Drug Therapy Approvals report is designed to showcase CDER's role in bringing safe and effective drugs to market for patients and consumers.This report describes CDER's 2024 notable drug approvals, which are actions we consider likely to have a significant impact on patient care and public health.These include novel drug approvals that contain a new active ingredient not previously approved by FDA.Also included are previously approved active ingredients that were also approved in 2024 to treat a different condition or new patient population.Throughout the report, we describe new therapies CDER approved in 2024 for safety and efficacy, as well as the regulatory tools used to streamline the review and approval of these applications.We approved most of these new treatments on or before their goal dates as defined by congressionally authorized agreements with industry (referred to as user fee programs).More than half of these drugs were approved in the U.S. before our regulatory counterparts in other countries did so.CDER's work on biosimilar biological products (biosimilars) reached several major milestones in 2024.CDER approved a record total of 18 biosimilars for 8 reference products in 2024, more than any previous year.We also surpassed our 60th biosimilar approval since 2015 when the first biosimilar was approved.In addition, this year 9 biosimilars, including those approved in 2024 and in previous years, were approved as interchangeable biosimilars, which means that they may be substituted for their reference product at the pharmacy without the intervention of the prescriber, subject to state law, similar to how generic drugs are substituted for brand name drugs.Our 2024 drug approvals include therapies for a variety of diseases and conditions, including rare diseases.FDA approved a significant number of rare disease therapies with orphan drug designation for patients with few to no treatment options.Therapies with orphan drug designations accounted for over 50% of our novel drug approvals, highlighting our steadfast commitment to address the huge unmet medical need in rare diseases.This year, we approved 26 novel therapies with this designation, including two of which treat conditions with no previously approved treatment such as Neimann-Pick disease type C and WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).This report is intended to feature CDER's 2024 notable approvals.FDA's Center for Biologics Evaluation and Research (CBER) also approves novel biologics and there are times when CDER and CBER may collaborate on certain approval actions.For more information on CBER's 2024 product approvals, please visit CBER's webpage for 2024 Biological Approvals�We hope this report illustrates CDER's hard work and unwavering commitment to advance patient care through the timely and thorough review and approval of safe and effective treatments.

Zitieren

APA

Pérez-Campos, E., González, E. E. J., & Cabrera-Fuentes, H. A. (2025). Biocomparables huérfanos en Latinoamérica: la urgencia de una regulación científica diferenciada. Latin american journal of clinical sciences and medical technology. https://doi.org/10.34141/ljcs1471963

Vancouver

Pérez-Campos E, González EEJ, Cabrera-Fuentes HA. Biocomparables huérfanos en Latinoamérica: la urgencia de una regulación científica diferenciada. Latin american journal of clinical sciences and medical technology. 2025. doi:10.34141/ljcs1471963

BibTeX
@article{PrezCampos2025,
  author = {Pérez-Campos, Eduardo and González, Efrén Emmanuel Jarquín and Cabrera-Fuentes, Hector A.},
  title = {Biocomparables huérfanos en Latinoamérica: la urgencia de una regulación científica diferenciada},
  journal = {Latin american journal of clinical sciences and medical technology},
  year = {2025},
  doi = {10.34141/ljcs1471963}
}
Kostenlos starten →